Clinical studies have shown that serum SAA levels are elevated two to threefold in patients with NASH compared to age-matched healthy controls [173], a finding corroborated by similar increases in Saa expression in murine models of NAFLD [69, 92]. Here, SAA1 is linked to metabolic dysfunction-associated steatotic liver disease.